Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma
Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with temozolomide may kill more tumor cells. It is not yet known which schedule of temozolomide when given together with radiation therapy is more effective in treating glioblastoma or gliosarcoma.
PURPOSE: This randomized phase III trial is studying two different schedules of temozolomide to compare how well they work when given together with radiation therapy in treating patients with newly diagnosed glioblastoma or gliosarcoma.
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to recursive partitioning analysis class (III vs IV vs V), MGMT gene methylation status (methylated vs nonmethylated vs indeterminate), and radiotherapy criteria used (standard vs revised European).
After completion of study treatment, patients are followed every 3 months for 1 year, every 4 months for 2 years, and then every 6 months thereafter.
Inclusion criteria:
Histopathologically proven diagnosis of glioblastoma. Since gliosarcoma is a variant of glioblastoma, gliosarcoma is also an eligible diagnosis.
Patients must have at least 1 block of tissue available for analysis of MGMT status; fresh frozen tumor tissue acquisition is encouraged.
Diagnosis must be established by open biopsy or tumor resection. Patients who have only had a stereotactic biopsy are not eligible.
The tumor must have a supratentorial component.
Patients must have recovered from the effects of surgery, postoperative infection, and other complications before study registration.
A diagnostic contrast-enhanced magnetic resonance imaging (MRI) or computerized tomography (CT) scan (if MRI is not available) of the brain must be performed preoperatively and postoperatively. The postoperative scan must be done within 28 days of registration and prior to the initiation of radiotherapy. Preoperative and postoperative scans must be the same type. If CT scans were performed perioperatively, a CT and an MRI should be performed before randomization.
6.1. Patients unable to undergo MRI imaging because of non-compatible devices can be enrolled, provided pre- and post-operative contrast-enhanced CT scans are obtained and are of sufficient quality.
Therapy must begin ≤ 5 weeks after the most recent brain tumor surgery.
History/physical examination within 14 days prior to study registration.
Neurologic examination within 14 days prior to study registration.
Documentation of steroid doses within 14 days prior to study registration and stable or decreasing steroid dose within 5 days prior to registration.
Karnofsky performance status of ≥ 60.
Age ≥ 18 years.
Complete blood count (CBC)/differential obtained within 14 days prior to study registration, with adequate bone marrow function as defined below: 13.1 Absolute neutrophil count (ANC) ≥ 1500 cells/mm3. 13.2 Platelets ≥ 100,000 cells/mm3. 13.3 Hemoglobin ≥ 10 g/dl. (Note: The use of transfusion or other intervention to achieve Hgb ≥ 10 g/dl is acceptable.)
Adequate renal function, as defined below:
14.1 Blood urea nitrogen (BUN) ≤ 25 mg/dl within 14 days prior to study registration 14.2 Creatinine ≤ 1.7 mg/dl within 14 days prior to study registration
Adequate hepatic function, as defined below:
15.1 Bilirubin ≤ 2.0 mg/dl within 14 days prior to study registration 15.2 Alanine aminotransferase (ALT) ≤ 3 x normal range within 14 days prior to study registration 15.3 Aspartate aminotransferase (AST) ≤ 3 x normal range within 14 days prior to study registration
Patients must sign a study-specific informed consent prior to study registration.
If the patient's mental status precludes his/her giving informed consent, written informed consent may be given by the responsible family member.
For females of child-bearing potential, negative serum pregnancy test within 72 hours prior to starting temozolomide.
Women of childbearing potential and male participants must practice adequate
Exclusion criteria:
Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for ≥ 3 years. (For example, carcinoma in situ of the breast, oral cavity, and cervix are all permissible).
Recurrent or multifocal malignant gliomas
Metastases detected below the tentorium or beyond the cranial vault.
Prior chemotherapy or radiosensitizers for cancers of the head and neck region; note that prior chemotherapy for a different cancer is allowable. Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment are not permitted. See Section 1.
Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation fields.
Severe, active co-morbidity, defined as follows:
Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.
Pregnant or lactating women, due to possible adverse effects on the developing fetus or infant due to study drug;
Prior allergic reaction to temozolomide.
Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the study.
No tissue provided for histopathologic central review and MGMT status.
Tissue provided by stereotactic biopsy method.
Fairbanks, Alaska 99701, United States
Sacramento, California 95815, United States
Boca Raton, Florida 33486, United States
Jacksonville, Florida 32207, United States
Tampa, Florida 33612-9497, United States
Boise, Idaho 83706, United States
Maywood, Illinois 60153, United States
Ottawa, Illinois 61350, United States
Peoria, Illinois 61615, United States
La Porte, Indiana 46350, United States
Des Moines, Iowa 50309, United States
Des Moines, Iowa 50314, United States
Wichita, Kansas 67214, United States
Dearborn, Michigan 48123-2500, United States
Grosse Pointe Woods, Michigan 48236, United States
Southfield, Michigan 48075, United States
Minneapolis, Minnesota 55407, United States
Robbinsdale, Minnesota 55422-2900, United States
Billings, Montana 59101, United States
Missoula, Montana 59807, United States
Keene, New Hampshire 03431, United States
Lebanon, New Hampshire 03756-0002, United States
Voorhees Township, New Jersey 08043, United States
Lake Success, New York 11042, United States
Manhasset, New York 11030, United States
Rochester, New York 14621, United States
Salem, Ohio 44460, United States
Portland, Oregon 97213-2967, United States
Portland, Oregon 97227, United States
Allentown, Pennsylvania 18105, United States
East Stroudsburg, Pennsylvania 18301, United States
Hershey, Pennsylvania 17033-0850, United States
Philadelphia, Pennsylvania 19107-5541, United States
Reading, Pennsylvania 19612-6052, United States
Wilkes-Barre, Pennsylvania 18711, United States
Charleston, South Carolina 29425, United States
Spartanburg, South Carolina 29303, United States
Sioux Falls, South Dakota 57117-5039, United States
Fort Worth, Texas 76104, United States
Murray, Utah 84157, United States
Burlington, Vermont 05401, United States
Seattle, Washington 98195-6043, United States
Yakima, Washington 98902, United States
Green Bay, Wisconsin 54301-3526, United States
Madison, Wisconsin 53792-6164, United States
Sturgeon Bay, Wisconsin 54235-1495, United States